Replies to post #142055 on Biotech Values

[biomaven0]

ibrutinib abstracts

Well a 100% ORR when combined with Azerra (Humax-cd20) in relapsed/refractory CLL/SLL (with some bad prognostics thrown in) and no GR 3 or higher SAEs is not something I will complain about!

Peter